A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)

By C. Apovian, L. Aronne, D. Rubino, C. Still, H. Wyatt, Colleen M. Burns, Dennis D. Kim, E. Dunayevich. Obesity, 2013

668 citations recorded by the source corpus.

To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight‐related risk factors in overweight and obese participants.

Subfields: Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/a166d673def862c0961394da6efe8bce95b123a6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Dagogo-Jack
2. Janet B. McGill
3. Irl B. Hirsch
4. George Grunberger
5. Zachary T. Bloomgarden
6. Daniel Einhorn
7. Joshua I. Barzilay
8. Ralph A. DeFronzo

Citations in the corpus

• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Whether achieved through lifestyle therapy, pharmacotherapy, surgery, or some combination thereof, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (44,48,49,51,53,60,63).”